Nampons - Shark Tank Update

Joshua Lippiner entered Shark Tank season 17 with Nampons, a discreet, medically approved solution designed to stop nosebleeds quickly and reliably-an everyday problem he believed had been overlooked for far too long. Seeking $350,000 for 5%, Joshua pitched Nampons as a simple but powerful first-aid upgrade, explaining how the product gently expands inside the nostril, applies consistent pressure at the source of bleeding, and uses a clotting agent to speed results without pain or mess.

While the Sharks acknowledged the usefulness of the product, concerns quickly arose around the valuation and the lack of patent protection on the core design, even as Joshua emphasized a growing pipeline of new products. Financially, the business impressed: launched in 2021, Nampons posted $3.4 million in sales in 2024, is on track for $3.8 million in 2025, and expects roughly $200,000 in net profit this year after heavy reinvestment into marketing and product expansion.

A six-pack costs $3.61 to manufacture and sells for $15.99, leaving healthy margins as the company prepares to enter retail. Robert Herjavec initially lobbed a “sharky” counter of $350,000 for 25%, but negotiations took a turn when Joshua introduced a royalty structure to preserve valuation-reigniting Kevin O’Leary’s interest and drawing Michael Strahan into the deal.

In the end, Robert and Michael teamed up, offering $350,000 for 10% equity plus a $0.10 per-unit royalty until they recoup their investment, a deal Joshua accepted. With Shark backing, growing medical credibility, and retail expansion on the horizon, Nampons left the Tank positioned to become a staple in medicine cabinets, schools, and sports bags nationwide.

After securing a deal with Robert Herjavec and Michael Strahan, Nampons entered its next phase with both capital and credibility. The Shark partnership helped accelerate conversations around retail placement, institutional sales, and broader first-aid distribution channels.

With FDA compliance already established and sales momentum strong, the company continued expanding beyond its core six-pack product while reinforcing its positioning as a serious medical solution rather than a novelty. Post-show visibility also helped normalize the product for schools, sports teams, and healthcare settings, where nosebleeds are common and fast intervention matters.

With profitability within reach and Sharks aligned on scale, Nampons exited the Tank poised for mainstream adoption.